Diligence memo · auto-generated · as of July 2, 2026
INIA Biosciences, Inc.
INIA Biosciences, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
INIA Biosciences, Inc. operates in Biotech / Pharma, based in Boston.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
INIA Biosciences, Inc. has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $200K on 2023-11-25.
Most recent recorded round closed around 2023-11-25.
Valuation (modeled)modeled
Provath models INIA Biosciences, Inc. at approximately $1.3M (range $109K–$5.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.62× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.6 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 16% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 11% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.